Department of Pathogenic Biology and Immunology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Centre, Xi'an, Shaanxi, China; Key Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education of China, Xi'an, Shaanxi, China.
Department of Pathogenic Biology and Immunology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Centre, Xi'an, Shaanxi, China; Key Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education of China, Xi'an, Shaanxi, China.
Neoplasia. 2020 Mar;22(3):142-153. doi: 10.1016/j.neo.2020.01.002. Epub 2020 Feb 12.
The BCL6 proto-oncogene encodes a transcriptional repressor, which is required for germinal centers (GCs) formation and lymphomagenesis. Previous studies have been reported that the constitutive expression of BCL6 leads to diffuse large B cell lymphoma (DLBCL) through activation-induced cytidine deaminase (AID) mediated chromosomal translocations and mutations. However, other DLBCLs (45%) without structural variants were characterized by abnormally high level of BCL6 expression through an unknown mechanism. Herein, we report that deficiency in AID or methyltransferase 1 (DNMT1) triggers high level of BCL6 expression. AID-DNMT1 complex binds to -0.4 kb -0 kb region of BCL6 promoter and contributes to generate BCL6 methylation which results in inhibition of BCL6 expression. The proteasome pathway inhibitor MG132 induces accumulation of AID and DNMT1, causes decreased BCL6 expression, and leads to cell apoptosis and tumor growth inhibition in DLBCL cell xenograft mice. These findings propose mechanistic insight into an alternative cofactor role of AID in assisting DNMT1 to maintain BCL6 methylation, thus suppress BCL6 transcription in DLBCL. This novel mechanism will provide a new drug selection in the therapeutic approach to DLBCL in the future.
BCL6 原癌基因编码一种转录抑制剂,它是生发中心(GCs)形成和淋巴瘤发生所必需的。先前的研究表明,BCL6 的组成性表达通过激活诱导的胞苷脱氨酶(AID)介导的染色体易位和突变导致弥漫性大 B 细胞淋巴瘤(DLBCL)。然而,其他没有结构变异的 DLBCL(45%)通过未知机制表现出异常高的 BCL6 表达水平。在此,我们报告 AID 或甲基转移酶 1(DNMT1)的缺失会触发高水平的 BCL6 表达。AID-DNMT1 复合物结合到 BCL6 启动子的-0.4 kb-0 kb 区域,并有助于产生 BCL6 甲基化,从而抑制 BCL6 的表达。蛋白酶体途径抑制剂 MG132 诱导 AID 和 DNMT1 的积累,导致 BCL6 表达降低,并导致 DLBCL 细胞异种移植小鼠的细胞凋亡和肿瘤生长抑制。这些发现为 AID 在协助 DNMT1 维持 BCL6 甲基化以抑制 DLBCL 中 BCL6 转录的辅助因子作用提供了机制上的深入了解。这种新的机制将为未来治疗 DLBCL 的药物选择提供新的途径。